Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | iCasp9M28z T cells |
Synonyms | |
Therapy Description |
iCasp9M28z T cells are autologous T-cells that express a chimeric antigen receptor targeting mesothelin, which potentially enhances anti-tumor immune response against mesothelin-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
iCasp9M28z T cells | anti-mesothelin iCasp9M28z | iCasp9M28z T cells are autologous T-cells that express a chimeric antigen receptor targeting mesothelin, which potentially enhances anti-tumor immune response against mesothelin-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02414269 | Phase I | Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Active, not recruiting | USA | 0 |